Safety and Effectiveness of ABT-510 Plus Combination Chemotherapy in Subjects With Non-Small Cell Lung Cancer (NSCLC)
Stopped Enrollment suspended based upon interim analysis; subjects allowed to stay on study until disease progression.
Conditions
- Carcinoma, Non-Small-Cell Lung
Interventions
- DRUG: ABT-510/Thrombospondin-1 mimetic
- DRUG: Carboplatin/Taxol
Sponsor
Abbott